Testosterone Replacement Therapy Following the Diagnosis of Prostate Cancer: Outcomes and Utilization Trends
Abstract
Late-onset hypogonadism may impair quality of life and contribute to metabolic and cardiovascular comorbidity in aging men. Testosterone replacement therapy is effective in treating hypogonadism. However, for the millions of men with a history of prostate cancer, exogenous testosterone has long been considered contraindicated, even though little data in such men are available. Clarification of this safety issue could allow treatment to be considered for a sizeable segment of the aging male population.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Apr 01, 2014
- Source ID
- 10.1111/jsm.12429
Entities
People
- Alan L. Kaplan
- Jim C. Hu
- Leonard S. Marks
- Maxine Sun
- Paul L. Nguyen
- Quoc-Dien Trinh
- Stacey C. Carter
- Ya-chen Tina Shih
Organizations
- Brigham and Women's Hospital
- United States Department of Defense
- University of California, Los Angeles
- University of Chicago
- Université de Montréal